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Since the discovery of anti-tumor activity of cisplatin in 1960, significant
progress has been made in treating metastatic or advanced cancer with cisplatin and
platinum compounds. Platinum compounds covalently bind to DNA and disrupt DNA
function. They are also known to bind with amino acids like methionine, histidine and
cysteine to form cisplatin-protein adducts which are responsible for most of its
cytotoxicity and side effects. Recent articles on cisplatin-protein have shown that adding
bulky adjuncts to cisplatin or using different platinum compounds varies the degree and
extent of reaction thus possibly reducing cisplatin resistance and side effects.
One of the proteins to study is cytochrome C, which is an intermediate in
apoptosis (a controlled form of cell death used to kill cells in the process of development
or in response to infection or DNA damage). Cytochrome C activates caspase 9, a
cysteine protease, which in turn goes on to activate caspases 3 and 7, which are
responsible for destroying the cell from within.
In this study, we tried to examine how various platinum compounds like cisPt(NH3)2Cl2, cis-Pt(NH3)2(NO3)2, Pt(en)(NO3)2, Pt(Me4en)(NO3)2, Pt(NH3)2 (oxalate),
Pt(en)(oxalate),Pt(Me4en)(oxalate), which have different ligands/bulk, react with
cytochrome C in different physiological conditions. This research project subsequently
focused on three main aspects: 1) to determine whether the concentration of platinum
compounds made a difference in the reaction rate, 2) to determine whether the pH of the

viii

buffer shows any difference in the reaction rate, 3) to determine how the ligands
coordinated to the platinum affected the rate. We used 1) HPLC with vitamin B12
(cyanocobalamin) as an internal standard. 2) Separate samples of platinum compounds
with bovine serum albumin were then subjected to dialysis and were then sent to the
Materials Characterization Center for analysis by ICP-AES spectroscopy.
In summary, the following conclusions are stated:
•

The leaving group, pH, bulk and the concentration play a very vital role in
determining the reaction rate for platinum-cytochrome C interactions.

•

Chlorides form excellent leaving groups followed by oxalates then nitrates.

•

Pt(en) reacts faster than Pt(NH3)2 which reacts faster than Pt(Me4en).

•

Nitrates, Pt(en) and few oxalate form multiple products showing non-specific
binding. Only cis-Pt(NH3)2Cl2 and Pt(Me4en)(oxalate) formed predominately a
single product showing target specific binding.

•

cis-Pt(NH3)2Cl2 showed an increased reaction rate at lower pH while cisPt(NH3)2(NO3)2 and Pt(Me4en)(NO3)2 showed higher reactions at higher pH.

•

Despite platinum compound was present in significant molar excess relative to
cytochrome C, at the end of 21 hrs there was a significant amount of unreacted
cytochrome C left except in case of cis-Pt(en)Cl2 which reacted with the whole
cytochrome C in less than ten minutes.
•

We saw the rate of reaction in order of cis-Pt(en)Cl2 > Pt(en)(oxalate) >

cis-Pt(NH3)2Cl2 > Pt(en)(NO3)2 > cis-Pt(NH3)2(NO3)2 > cis-Pt(NH3)2(oxalate) >
Pt(Me4en)(oxalate) > Pt(Me4en)(NO3)2
•
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I.

INTRODUCTION TO PLATINUM COMPOUNDS

1) History
As a compound, cisplatin, cis-Pt(NH3)2Cl2, was first described by M. Peyrone in
18451. He called it the Peyrone's salt. The molecular structural differences between
cisplatin and transplatin complexes were solved by Werner in 1890; he established thus
the basis of modern coordination chemistry. In the 1960s, B. Rosenberg found that use of
a platinum electrode inhibited binary fission in E. coli bacteria when an electric field was
created. The bacteria grew to 300 times their normal lengths, but cell division failed.
Rosenberg’s studies of the anti growth factors and his results with sarcoma 180
and leukemia L1210 cells aroused interest at the National Cancer Institution2, and soon
cisplatin was tested and established as a drug with curative ability in testicular cancers.
Research was done predominantly at Michigan State University to test the effects of the
cisplatin along with other platinum complexes, on tumors artificially implanted in rats2.
This study found that cisplatin was the most effective out of this group. Phase I clinical
trials started in 1971, and Food and Drug Administration approval was obtained in 1978
under the name Platinol. Carboplatin (C6H14N2O4Pt) followed with Food and Drug
Administration approval in 1989 under the name Paraplatin, whereas most recently
oxaliplatin (Eloxatin) 3 also was added for routine treatments of colon cancer and others
are in Phase I and Phase II clinical trials.
2) Synthesis of Cisplatin
Cisplatin can be synthesized by many procedures5, including:

1

2
Heating of tetraammineplatinum(II) chloride at 250°C

•

Reaction of ammonium carbonate with tetrachloroplatinic(II) acid

The following preparation is a modification of Ramberg and Peyrone respectively, and
involves a minimum number of side reactions to maximize yield.
Overall reaction scheme:
2K2 [PtCl6] + N2H4.2HCl
K2 [PtCl4] + 2NH3

•

2K2 [PtCl4] + N2 + 6HCl
cis-[Pt (NH3)2 Cl2] + 2KCl

Addition of ammonia to ammonium tetrachloroplatinate(II)

Cisplatin is also commercially available and can be purchased from SigmaAldrich.
3) Types of compounds
Platinum has two dominant valence states, + 2 and + 41; the former state forms
square planar complexes and the latter forms octahedral complexes. The earliest

3
synthesized anti-tumor drugs were cis-[PtII(NH3)2Cl2] and cis-[PtIV(NH3)2Cl4]. Most of
the well-known platinum anticancer complexes have the general formula cis-[PtX2
(NHR2)2], in which R = organic fragment and X = leaving group, such as chloride
or (chelating bis) carboxylate. Cisplatin showed a 90% curative rate for ovarian and
testicular cancer. Trans-diamminedichloroplatinum (II) (Trans-DDP, or transplatin), the
geometric isomer of cisplatin is clinically ineffective. Carboplatin, cis-diammine-1, 1’cyclobutane dicarboxylate platinum (II) (Figure 1.1), had reduced toxicity but was cross
resistant with cisplatin. Oxaliplatin, trans-l-diamino-cyclohexane-oxalatoplatinum (II),
displayed a lack of cross-resistance and is used to treat colon tumors3. Many more oral
compounds are being synthesized every year, there are over 3000 cisplatin analogs that
have been tested3, with 28 that are awaiting clinical trials. It is estimated that more than
10,000 compounds need to be screened in order to obtain a new, effective anticancer
drug.

Figure 1.1. Structures of cisplatin (1) and some first-generation drugs: Carboplatin (2);
Nedaplatin (3); Oxaliplatin (4), an orally active drug (5, JM-216) and some recently

4
introduced new mononuclear (6, AMD473); dinuclear (7) and trinuclear (8) Pt-antitumor
drugs. 2
4) Physical and Chemical Properties
I will be discussing cisplatin for the rest of the paper; its physical properties are
Table 1: Physical properties of cis-diamminedichloroplatinum (II) 4
cisFormal Name
diamminedichloroplatinum(II)
Common/Commercial
Cisplatin/Platinol
Names
Agent

Anti-neoplastic

Molecular Formula

Cl2H6N2Pt

Figure 1.2: cis-

Molecular Weight

300.1

Pt(NH3)2Cl2

Normal State

Crystalline solid

Color

Deep yellow (crystalline solid) & Clear (reconstituted
solution)

Structure

Tetragonal (square) planar

Symmetry

C2V

Melting Point

Decomposes at 270°C to give chlorine gas and nitrogen
oxides

•

Reactivity4
Cisplatin is incompatible with oxidizing agents and aluminum. Cisplatin reacts
with aluminum and becomes inactivated permanently. It is therefore, not administered
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with aluminum hubbed needles. Cisplatin may react with sodium bisulfite and other
antioxidants.

•
•

Stability4
Cisplatin and Water
NMR and UV spectrophotometric stability screenings indicate that solutions of
cisplatin in DMSO are stable for less than two hours. It slowly changes to the transisomer in aqueous solution. The Cl ligands are substituted with aqua ligands. The
resulting di-aqua complex has a half- life of about 5 hours at 30°C at pH 7. A dramatic
increase in stability is observed when the chloride ion is added. Fresh solutions are
therefore prepared in saline before use. Cisplatin is stable under normal laboratory
conditions.

•

Cispatin–DNA Complexes:
An important property of the platinum coordination compounds is the fact that the
Pt–ligand bond, has the thermodynamic strength of a typical coordination bond (~100
kJ/mol) and is much weaker than (covalent) C—C and C—N or C—O single and double
bonds (which are between 250 and 500 kJ/mol). 7 However, the ligand-exchange behavior
of Pt compounds is quite slow, which gives them a high kinetic inert and results in
ligand-exchange reactions of minutes to days, rather than microseconds to seconds for
many other coordination compounds.
5) Biological reactions of Cisplatin
Upon administration, a chloride ligand undergoes slow displacement with a water
(an aqua ligand) molecule, in a process termed aquation. The aqua ligand in the resulting

6
[PtCl(H2O)(NH3)2] + is easily displaced, allowing cisplatin to coordinate to a basic site in
DNA. Subsequently, the platinum cross-links a second base via displacement of the other
chloride ligand.1 Cisplatin cross-links DNA in several different ways, interfering with
cell division by mitosis. The damaged DNA elicits DNA repair mechanisms, which in
turn activate apoptosis when repair proves impossible. 6
Most notable among the DNA changes are the 1, 2-intrastrand cross-links with
purine bases. These include 1, 2-intrastrand d(GpG) adducts, which form nearly 90% of
the adducts formed, and the less common 1, 2-intrastrand d(ApG) adducts. 1, 3intrastrand d(GpXpG) adducts occur but are readily excised by the nucleotide excision
repair (NER). Other adducts include inter-strand cross links and nonfunctional adducts
that have been postulated to contribute to cisplatin's activity. Interaction with cellular
proteins, particularly HMG domain proteins, has also been advanced as a mechanism of
interfering with mitosis, although this is probably not its primary method of action

Figure 3: Hydrolysis pathways complex of cis-diamminedichloroplatinum (II) 6

Equilibrium processes for cisplatin in cancer cells

Scheme 1: Equilibrium processes for cisplatin in cancer cells 7
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Equilibrium processes for cisplatin in cancer cells

Scheme 1: Equilibrium processes for cisplatin in cancer cells 7
Cationic platinum complexes, such as [Pt (NH3)2 (OH2) Cl] +, are formed when a water
molecule attacks the platinum metal center, thus eliminating a chloride ion, which acts as
a non-coordinating anion. The cell essentially traps the cisplatin by transforming it into a
cationic component of a neutral molecule. After losing two Cl- ions, hydrolyzed cisplatin
reacts with DNA, coordinating to nitrogen atoms of the nucleobases. The active species
in the cell is thus (NH3)2Pt2+, not cisplatin 6. The binding of (NH3)2Pt2+ to DNA leads to
changes in the DNA structure. NMR studies indicate that the Pt2+ binds to N7 atoms of a
pair of guanine bases on adjacent strands of DNA.
6) DNA Damage and Apoptosis
Studies showed that cisplatin arrested cell mitosis in the G2 phase by blocking
transcription. Cells treated with low concentrations of cisplatin recovered from the G2
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phase arrested, while cells treated with higher concentrations of the drug had only a
limited number of survivors. Gel electrophoresis studies identified the mechanism of cell
apoptosis which showed nucleotides in form of ‘nucleosome ladder’ 9.
7) Structural studies of Cisplatin – DNA Adducts
As noted above, cisplatin – DNA adducts are the cause of the cytotoxicity of the
drug. These cisplatin DNA adducts cause a distortion of the DNA. Calorimetric studies
showed cisplatin binding could unwind DNA and, at saturation levels, shorten the duplex
by up to 50%. This resulted in loss of helix stability. Further calorimetric studies
experiment with site specific cisplatin DNA adducts revealed a duplex destabilization of
6.3 kcal/mol association with cis – GG adduct formation. 7
X-ray crystallography revealed the nature of the cis- GG cross link on the
dinucleotide d(pGpG) and trinucleotide d(CpGpGp)8. NMR work combined with
molecular mechanics calculations on duplex DNA containing a cisplatin 1,2- intrastrand
d(GpG) adduct showed that the adduct caused the helix to bend approximately 60◦
towards the major groove. NMR even helped determine the structure of 1,2 intrastrand
d(GpG) 8.
Gel electrophoresis studies were also employed to gain structural information
about various site specific cisplatin DNA adducts. Studies using multimers of a 22 – bp
oligonucleotide containing a 1,2 interstrand d (GpG) cisplatin cross link showed that the
DNA bends approximately 40° in the direction of the major groove8 and were extended
to examine the DNA bending and unwinding induced by other adducts of cisplatin and
Trans – DDP8.
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8) Alternative Cellular DNA targets
Most research was oriented towards genome DNA (gDNA), but soon an
alternative cellular DNA target was identified. Mitochondrial DNA (mtDNA), 9 which
lacks histones, has been targeted by DNA-damaging agents such as methylnitrosourea,
alfatoxin B1 and bleomycin5.
Using dissociation enhanced lanthanide fluoro immunoassay (DELFIA) and
immunoelectron microscopy, researchers measured the number of cisplatin DNA
adducts. They found there was a six-fold and four-fold higher proportion of adducts in
mtDNA, compared to gDNA6. The preference for mtDNA was later attributed both to
higher initial binding and to the lack of removal of the cisplatin DNA adducts.
9) Need to study protein interaction with cisplatin drugs
9.1) Introduction
Over the past 42 years since the discovery of the biological activity of cisplatin, much
has been learned about how this drug affects the cell, and the DNA interactions have been
studied8. Despite the fact that DNA adducts are primarily responsible for the anticancer
activity, up to 75-85% of the covalently bound cell associated cisplatin has been found to
be bound to protein5. Cisplatin toxicity and side effects can be attributed to some of these
protein interactions.
9.2) Cisplatin toxicity and side effects:
Cisplatin toxicity is thought to be related with competitive protein binding of Pt
compounds. This toxicity can be seen in the form of nephrotoxicity (kidney damage),
neurotoxicity (nerve damage), ototoxicity (hearing loss) and other common side effects of
chemotherapy such as nausea, vomiting, alopecia (hair loss) and electrolyte disturbance.
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On its way to the ultimate destination, platinum complexes interact with many
other biomolecules because of kinetic and thermodynamic competition in the blood and
in the tissues, especially those containing S-donor ligands, such as amino acids side chain
in methionine, and cysteine residues17. Pt also binding with lone pairs of nitrogen atoms,
which can occur in amino acids such as histidine, is seen in the absence of S-donor
ligands.
Also cisplatin can enter the cell with both active and passive mechanisms. Active
transport requires a channel or transport protein. Platinum can coordinate to the nitrogen
of DNA and/or oxygen atoms of a peptide backbone, thus forming Pt-DNA-protein
adducts. Many researchers believe that the DNA protein adducts contribute to high
toxicity of cisplatin.
It has been found that platinum protein complexes containing a thiol group e.g.
glutathione provides a detoxification pathway and causes resistance. Blood proteins rich
in thiolates can deactivate cisplatin and these deactivated cisplatin is responsible for more
side effects as well as resistance.
9.3) Cellular resistance to cisplatin 9
The efficacy of the chemotherapy drug cisplatin is often limited due to resistance
of the tumors to the drug, and increasing the potency of cisplatin without increasing its
concentration could prove beneficial. Resistance to cisplatin can either be intrinsic to the
cell or acquired through exposure to the compound. Cellular resistance to these drugs is
multifactorial and consists of complex mechanisms with a wide array of related and
unrelated pathways. Some of the mechanisms identified to date are:

11

•

Limit the formation of lethal platinum-DNA adducts (altered drug transport,
inactivation); 9

•

Enable and enhance DNA repair, dependent and independent of signal
transduction pathways; 9

•

Enable cells to tolerate platinum-DNA damage once it occurs. This may include
altered genomes which up regulate bcl-2 and other death antagonists; 9

•

Enhance intracellular detoxification such as by an increased reflux or increased
inactivation by sulfhydryl molecules such as the glutathione (GSH) and metallothionein
pathways. 9

Thus to avoid this resistance, second generation drugs are coming to the market
The design and development of these cisplatin analogs have revealed common
requirements that are necessary for its use as an anticancer drug.
These common requirements are:

•

Electro-neutrality, to allow for it to pass through non-polar substances such as cell
membranes; 10

•

Presence of at least two good leaving groups, preferentially cis to one another.
This allows for DNA and/or protein binding. 10

•

Presence of "inert" carrier ligands, usually non-tertiary amine groups which
increase adduct stabilization through hydrogen bonding with nearby bases10.
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Using these criteria as bases, present research focuses on
platinum complexes that are most likely are going to be active. With
such relatively broad requirements, new platinum based anticancer
drugs can therefore have totally different structures to cisplatin.
There have been developments of octahedral platinum (IV) complexes, one of which is in
clinical use iproplatin (cis-dichloro-trans-dihydroxy-cis-bis (isopropyl amine) platinum
(IV)) [CHIP], trans-platinum complexes, and even bis-platinum complexes. Even the
introduction of such aromatic N-containing ligands as pyridine, imidazole and 1,10phenanthroline, and their derivatives (whose donor properties are somewhat similar to the
purine and pyrimidine bases) to anti tumor agents are drawing attention12.

The ability to bind through two metal atoms could lead to a more potent and
active drug over a larger spectrum of cancers, including cisplatin resistant types. A study
of the complex [cis-PtCl2(NH3)]2H2N(CH2)4NH2 showed it to be active against some
cancer cells by forming covalent bonds with DNA and DNA repair proteins, thus
separating the two and preventing repair11

Forming new drugs using bulky ligands has also been being studied. It has been
found that cisplatin & cisplatin analogs containing one bulky amine function reacted
similarly to form DNA adducts. Further studies with increase in amine, bulk showed a
decrease in the formation of methionine adducts, suggesting that the bulk can affect the
types of adducts formed in protein13. These studies utilized mass spectrometry, which
detects the platinum binded to protein. Also 15N NMR spectroscopy has been utilized for
identifying the site of reaction of platinum with protein.
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9.4) Why study cytochrome C?
Cytochrome C, or cyto C (horse heart: PDB 1HRC) is a positively charged small
heme protein (heme group that allows detection in the visible range—410nm) found
loosely associated with the inner membrane of the mitochondrion. Unlike other
cytochromes, it is a soluble protein. Also it is commercially available and easy to use.
Cytochrome C is also an intermediate in apoptosis, a controlled form of cell death
used to kill cells in the process of development or in response to infection or DNA
damage.14 This small amount of cytochrome C leads to the endoplasmic reticulum to
release calcium. The overall increase in calcium triggers a massive release of cytochrome
C, which then acts in the positive feedback loop to maintain ER calcium release. This
explains how the ER calcium release can reach cytotoxic levels.
Also cytochrome C is rapidly released from HNSCC mitochondria treated with
increasing doses of cisplatin with studies done on mitochondria from cisplatin-sensitive
head and neck cancer cell line PCI-13. Supernatant from the treated mitochondria was
collected and assayed for cytochrome C release by Western blot. Cisplatin doses as low
as 12.5 µmol/L cause significant cytochrome C release. Also it was found that an
identical dose of the inactive stereoisomer transplatin (TDDP) did not cause significant
cytochrome c release from mitochondria.16
Also, this release of cytochrome C activates caspase 9, a cysteine protease.
Caspase 9 can then go on to activate caspases 3 and 7, which are responsible for
destroying the cell from within. A study was done to find which pathway cisplatin
resistant and cisplatin sensitive cells take. It showed that cisplatin-induced apoptosis
proceeds by caspase-3-dependent in cisplatin-resistant and caspase-3-independent
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pathways for cisplatin sensitive human ovarian cancer cell lines.15 Thus proving that
cytochrome C is one of the many reasons for cisplatin resistance.
Thus studying recent articles on cisplatin-protein, and the role of cytochrome C in
apoptosis we see that adding bulky adjuncts to cisplatin or using different platinum
compounds varies the degree and extent of reaction of cisplatin with cytochrome C. We
hope to reach a better understanding of platinum compound reaction to cytochrome C.

II.

METHODS AND MATERIALS

The aim of the current research is to examine how selected platinum compounds
with different ligands react with proteins at different physiological conditions
1. Concentration studies:
Initially, cis-Pt(NH3)2Cl2, cis-Pt(NH3)2(NO3)2, Pt(en)(NO3)2, and
Pt(Me4en)(NO3)2 were dissolved in concentrations of 1 mg and 3 mg in 3 ml buffer
reacted each with 3 mg of bovine albumin. These samples were then subjected to dialysis
where all unbound cisplatin was removed. The samples were dried and 20 ml of
deionized water was added. The samples were then sent to the Materials Characterization
Center (MCC) for analysis by ICP-AES spectroscopy.
Also, HPLC analysis utilized several platinum complexes such as cisPt(NH3)2Cl2, cis-Pt(NH3)2(NO3)2, Pt(en)(NO3)2, Pt(Me4en)(NO3)2, cis-Pt(NH3)2 (oxalate),
Pt(en)(oxalate), Pt(Me4en)(oxalate) that were reacted with cytochrome C with an internal
standard of vitamin B12 (cyanocobalamin). Cytochrome C had an elution time between
15-17 minutes, while vitamin B12 had an elution time between 1.5-2 minutes. The
products formed where seen around the Cytochrome peak. A cation exchange column
was used to separate the products that were formed. A Hitachi Elite LaChrom pump L2130 was used with a flow rate of 0.5 mL/min; buffer A was 20 mM phosphate buffer
(pH 6), buffer B was buffer A + 0.5 M NaCl. An elution gradient went from 20% B to
50% B from time = 0 to 30 min.
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2. pH studies:
Each platinum compound was dissolved in concentrations of 0.5 mg, 1 mg, 1.5 mg, and 3
mg in 3 ml buffer reacted each with 3 mg of bovine serum albumin in phosphate buffer at
a pH of 6 and 7. These samples were dialyzed and sent to the MCC as described above.
3. Time studies:
Each platinum compound was treated with bovine albumin for the time period of
1 hr, 3 hrs, 6 hrs, 12/24 hrs. These samples were then run through dialysis where all
unbound cisplatin was removed. The samples were dried and 20 ml of deionized water
was added. The samples were sent to the MCC for analysis as described above.
Also, each platinum compound was reacted with cytochrome C in the presence of
an Internal Standard of Vitamin B12 (cyanocobalamin) for the time period of 0 hr, 3 hrs,
6 hrs, 9 hrs, 12 hrs, 15 hrs, 18 hrs and 21 hrs. The samples were studied by HPLC as
described above.
Materials used
Buffers: Phosphate buffer (pH 6 and 7), N, N’- Diisopropylethylamine buffer (pH 4)
Chemicals: Cisplatin cis-Pt(NH3)2Cl2 99.9+% (Sigma Aldrich),
Silver nitrate (AgNO3),
Dichloroethylenediamine platinum (II) 99% (Sigma Aldrich),
Oxalic acid (C2H2O4) anhydrous p.a (ACROS Organic),
Potassium tetrachloroplatinate(II) (K2PtCl4) 98% (Sigma Aldrich),
Cytochrome C from horse heart 98% (Sigma Aldrich),
Albumin from bovine serum, minimum 98% electrophoresis (Sigma Aldrich),
Vitamin B12 (cyanocobalamin) 99% purity,
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Potassium phosphate (KH2PO4) monobasic reagent ACS crystals (ACROS),
Sodium phosphate dibasic (Na2HPO4) reagent suitable for buffer solution (ACROS),
Sodium Chloride p.a (NaCl) (ACROS),
N,N’- Diisopropylethylamine biotech grade solvent 99.5% (Sigma Aldrich)
pH for N, N’- Diisopropylethylamine buffer adjusted using concentrated Acetic acid,
Glacial (Fisher Scientific).
Pt-Complex synthesis
Pt(Me4en)Cl2 were synthesized as described previously.18
Silver oxalate was prepared by mixing silver nitrate and oxalic acid in equimolar
amounts in H2O and stirring in an amber vial overnight; the silver oxalate precipitate was
collected by vacuum filtration and rinsed with water.
The nitrate or oxalate forms of each platinum compound were prepared by mixing silver
nitrate or silver oxalate with the platinum dichloride compound in an aqueous solution at
a 2:1 molar ratio of Ag:Pt. The solutions were stirred in an amber vial for one or more
days, after which they were filtered and evaporated to dryness.

III.

RESULTS

Observations with HPLC
Comparing cis-Pt(NH3)2Cl2, cis-Pt(NH3)2(NO3)2 and cis-Pt(NH3)2(oxalate) , for
the effect of leaving groups we found that cis-Pt(NH3)2Cl2 (with 17% of unreacted
cytochrome C) reacted faster than cis-Pt(NH3)2(NO3)2 (with 71 % of unreacted
cytochrome C) and cis-Pt(NH3)2(oxalate) (with 71% of unreacted cytochrome C). cisPt(NH3)2(NO3)2 and cis-Pt(NH3)2(oxalate) reacts almost equally with cis-Pt(NH3)2(NO3)2
being very slightly faster, though at the end their reaction rate is almost equal (Figure
3.18) at the same pH, over the time period of 21 hrs at the same concentration. We also
saw that cis-Pt(NH3)2Cl2 (Figure 3.8) gave one major product when reacted with
cytochrome C, while cis-Pt(NH3)2(NO3)2 (Figure 3.10) and cis-Pt(NH3)2(oxalate) (Figure
3.18) gave multiple products. We also noted that the reaction rate was faster when 4 mg
of cis-Pt(NH3)2Cl2 (Figure 3.8) (with 17% of unreacted cytochrome C), cisPt(NH3)2(NO3)2 (with 71% of unreacted cytochrome C) and cis-Pt(NH3)2(oxalate) (with
71% of unreacted cytochrome C) (Figures 3.20 and 3.21) were reacted with 1 mg
Cytochrome C compared to reaction rate for 1 mg cis-Pt(NH3)2Cl2 (Figure 3.9) (with 55%
of unreacted Cytochrome C), cis-Pt(NH3)2(NO3)2 (with 83% of unreacted cytochrome C)
and cis-Pt(NH3)2(oxalate) reacting with 1 mg cytochrome C. Also the reaction rate was
almost negligible at the end of 2nd day for cis-Pt(NH3)2Cl2 and cis-Pt(NH3)2(NO3)2.
Comparing Pt(en)Cl2 Pt(en)(NO3)2, and Pt(en)(oxalate) for the effect of leaving
groups we found that cis-Pt(en)Cl2 reacted faster than cis-Pt(en)(oxalate) (Figure 3.17)
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which in turn was faster than cis-Pt(en)(NO3)2 at the same pH, over the time period of 21
hrs at the same concentration. In fact cis-Pt(en)Cl2 reacts so fast that with the standard 4
mg we observed a complete reaction in less than a 10 min period. Hence we did the
reaction with 8 mg cytochrome C to 1 mg cis-Pt(en)Cl2 which showed multiple products
(Figure 3.16). While Pt(en)(NO3)2 (Figure3.11) 1 mg tends to give one major product
which has a very similar elution time to cytochrome C, it also gives a second major
product after around 15 hrs of reaction. But cytochrome C when reacted with 4 mg
Pt(en)(oxalate) (Figure 3.17) gave multiple products which had an earlier elution time
than cytochrome C.
Comparing Pt(Me4en)(NO3)2 and Pt(Me4en)(oxalate) for the effect of leaving
groups we found that Pt(Me4en)(oxalate) reacted faster than Pt(Me4en)(NO3)2 which was
not expected at the same pH, over the time period of 21 hrs at the same concentration.
We also saw that Pt(Me4en)(oxalate) (Figures 3.14 and 3.15) forms one major product
which has very similar elution time to cytochrome C after around 12 hrs of reaction
while Pt(Me4en)(NO3)2 (Figure 3.13) gave multiple products . Also for Pt(Me4en)(NO3)2
the reaction rate showed no significant change between the end of the first day compared
to that at the end of the second day.
Comparing cis-Pt(NH3)2(NO3)2, Pt(Me4en)(NO3)2, and Pt(en)(NO3)2 (Figure 3.19)
for the effect of bulk we found that Pt(en)(NO3)2 (with 47 % of unreacted cytochrome C)
reacted faster than cis-Pt(NH3)2(NO3)2 (with 71% of unreacted cytochrome C) which in
turn reacted faster than Pt(Me4en)(NO3)2 (with 87% of unreacted cytochrome C) at the
same pH, over the time period of 21 hrs at the same concentration, each of them gave
multiple products (Figures 3.10, 3.11, and 3.13). For cis-Pt(NH3)2Cl2 and cis-Pt(en)Cl2,
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since cis-Pt(en)Cl2 reacts very fast, comparing 0.25mg cis-Pt(en)Cl2 to 4 mg cisPt(NH3)2Cl2 with 1 mg cytochrome C we saw that cis-Pt(en)Cl2 (Figure 3.16) gave
multiple products while cis-Pt(NH3)2Cl2 (Figure 3.8) gave one major product.
Comparing the cis-Pt(NH3)2(oxalate) (Figure 3.9), Pt(Me4en)(oxalate) (Figure
3.15), and Pt(en)(oxalate) (Figure3.16) we found that Pt(en)(oxalate) reacted faster than
both cis-Pt(NH3)2(oxalate), which in turn reacted faster than Pt(Me4en)(oxalate) at the
same pH, over the time period of 21 hrs at the same concentration, we also saw that cisPt(NH3)2(oxalate) and Pt(en)(oxalate) gave multiple products while Pt(Me4en)(oxalate)
forms one major product which has a very similar elution time to cytochrome C after
around 12 hrs of reaction. Pt(en)(oxalate) (Figure 3.17) was the only compound to have a
peak with an earlier elution time than cytochrome C.
Observations with Dialysis and ICP-AES spectroscopy
After dialysis (removal of unbound platinum), we found the amount of reacted
cis-Pt(NH3)2)(NO3)2 was greater than cis-Pt(NH3)2Cl2 (Figures 3.2 and 3.3), which
comparing the above data seem opposing. However it should be noted that with HPLC
we are comparing unbound cytochrome C whereas with dialysis we are comparing the
platinum bound to protein; thus, having more than one platinum bound to the same
protein would not cause additional decreases to unreacted protein by HPLC. Also for
HPLC we used cytochrome C, whereas for dialysis we used albumin.
We also saw in cis-Pt(NH3)2Cl2 (Figure3.5) and Pt(Me4en)(NO3)2 (Figure3.4)
with increase in pH (Comparing to pH 6, and pH 7) the amount of platinum bound to
protein increased, suggesting a higher reaction rate at higher pH for but for
Pt(NH3)(NO3)2 (Figure3.6) the trend was reversed.

IV.

CONCLUSIONS

We used HPLC and ICP-AES spectroscopy for our experiments. ICP-AES
spectroscopy gives the exact amount of platinum bound to the protein, giving us a more
accurate rate of reaction. We used albumin to react with platinum because albumin is
large enough not to pass through the dialysis tube, cheap and easily available. This is a
good procedure, but as we used phosphate buffer, any delay in forwarding the sample to
MCC for analysis would result in bacterial growth. Also because each time point sample
was done individually, the possible mechanical error of getting exactly 3 mg of platinum
compounds and protein increased. Also because the final amount of analysis was
sometimes as low as 3 ppm in 20 ml the possibility of error was high, hence we shifted to
HPLC. Not to mention the cost of analysis was lower than ICP-AES spectroscopy.
HPLC gives us the amount of unreacted Cyto C; we can see the cyto C peak go
down over the period of time. As the same sample is used for analysis over 21 hrs period
the human error of getting exactly 3 mg is greatly reduced. Also by adding an internal
standard we can compare the internal standard peak and unreacted Cyto C peak at time 0
hrs of reaction and thus get a percentage of unreacted Cyto C at later time points. The
only drawback to these is that for compounds that interact at multiple points at a single
Cyto C molecule, it is difficult to get the reaction rate easily. Also some Pt compounds
gave peaks with very close elution time of Cyto C which were hard to integrate.
Comparing the effects of leaving group, we saw that that chloride is an excellent
leaving group as can be seen in the cases of cis-Pt(en)Cl2 and cis-Pt(NH3)2Cl2. The other
21

22
leaving group that was fast was oxalate: Pt(en)(oxalate) and Pt(Me4en)(oxalate) had
faster reaction rates than either Pt(en)(NO3)2 or Pt(Me4en)(NO3)2. Also the reaction rate
for cis-Pt(NH3)2(oxalate) and cis-Pt(NH3)2(NO3)2 were almost the same. We also see that
the oxalates, cis-Pt(NH3)2(oxalate) and Pt(en)(oxalate), always give multiple products
while the nitrate, cis-Pt(NH3)2(NO3)2 and Pt(Me4en)(NO3)2, form multiple products
Pt(en)(NO3)2 forms more than one product after 15 hrs, suggesting a non-specific binding
of nitrate and oxalate with Cyto C. Comparing the effects of bulk we also see that
Pt(en)X2 compounds were faster to react than Pt(NH3)2X2 compounds which were in turn
faster than Pt(Me4en)X2 compounds. We also noted that Pt(en)X2 compound form
multiple peaks suggesting a non-specific binding of Pt(en)X2 with Cyto C comparing the
effects of pH we see that cis- Pt(NH3)2Cl2 react faster as you lower the pH which is
expected4, but Pt(Me4en)(NO3)2and cis-Pt(NH3)2(NO3)2 show an reverse trend,
suggesting nitrates leave faster at higher pH, while chloride leave faster at lower pH.
We found that although platinum compound were reacted in significant molar
excess compared to cyto C, cis-Pt(en)Cl2 was the only compound which when treated
with 1 mg of cyto C left no unreacted cyto C, closely followed by Pt(en)(oxalate) which
left ≈9% unreacted cyto C, while cis-Pt(NH3)2Cl2 left 17% of unreacted cyto C at the end
of 21 hrs. All the rest left a significant amount of unreacted cyto C from 47%
(Pt(en)(NO3)2) to 87%(Pt(Me4en)(NO3)2).
Thus the reaction rate for all platinum compounds according to HPLC:
cis-Pt(en)Cl2 > Pt(en)(oxalate) > cis-Pt(NH3)2Cl2 > Pt(en)(NO3)2 > cisPt(NH3)2(NO3)2 > cis-Pt(NH3)2(oxalate) > Pt(Me4en)(oxalate) > Pt(Me4en)(NO3)2
Figures
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Figure 3.1. ICP-AES data from reaction of 3 mg cis-Pt(NH3) 2Cl2 with 3 mg Albumin

1mg cis-Pt(NH3)2(NO3)2 reacted with 3mg Albumin
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Figure 3.2. ICP-AES data from reaction of 1 mg cis-Pt(NH3) 2Cl2 with 3 mg albumin
1 mg cis-Pt(NH3)2Cl2 reacted with 3mg Albumin
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Figure 3.3. ICP-AES data from reaction of 1 mg cis-Pt(NH3) 2(NO3)2 with 3 mg albumin
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Figure 3.4. ICP-AES data from reaction of Pt(Me4en)(NO3) 2 with 3 mg albumin over
time for pH 6 and pH 7
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Figure 3.8. HPLC data from reaction of cis-Pt(NH3)2Cl2 4 mg + cyto C 1 mg
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Figure 3.9. HPLC data from reaction of cis-Pt(NH3)2(oxalate) 1 mg + cyto C 1 mg
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Figure 3.10. HPLC data from reaction of cis-Pt(NH3)2(NO3)2 4 mg + cyto C 1 mg
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Figure 3.11. HPLC data from reaction of Pt(en)(NO3)2 4 mg + cyto C 1 mg
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Figure 3.12. HPLC data from reaction of Pt(en)(oxalate) 1 mg + cyto C 1 mg
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Figure 3.13. HPLC data from reaction of Pt(Me4en)(NO3)2 4 mg + cyto C 1 mg
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Figure 3.14. HPLC data from reaction of Pt(Me4en)(oxalate) 1 mg + cyto C 1 mg
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Figure 3.15. HPLC data from reaction of Pt(Me4en)(oxalate) 4 mg + cyto C 1 mg
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Figure 3.16. HPLC data from reaction of Pt(en)Cl2 1 mg + cyto C 8 mg
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Figure 3.18. Comparison of HPLC data from reaction of cis-Pt(NH3)2Cl2,
cis-Pt(NH3)2(NO3)2, cis-Pt(NH3)2(Oxalate) with cyto C

Figure 3.19. Comparison of HPLC data from reaction of cis- Pt(NH3)2(NO3)2,
Pt(Me4en)(NO3)2 and Pt(en)( NO3)2 with cyto C
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Figure 3.20. Comparison of HPLC data from reaction of rate cis-Pt(NH3)2Cl2
Concentrations 1 mg and 4 mg

Figure 3.21. Comparison of HPLC data from reaction of rate cis-Pt(NH3)2(NO3)2
concentrations 1 mg and 4 mg

V.

BIBLIOGRAPHY

1) Lippert, B. Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug.
Weinheim, Germany: Wiley; 1999.
2) Reedijk, J.; Teuben, J M. Cisplatin, Chemistry and Biochemistry of a Leading Anticancer
Drug. Lippert B., editor. Weinheim, Germany: Wiley; 1999. pp. 339–362
3) Jamieson Elizabeth R.: Lippard Stephen J.”Structure, Recognition, and Processing of
Cisplatin-Adducts”. Chemical .Review. 1999, 99, 2467 – 2498
4) Housecroft, C E.; Sharpe, A G. “Mechanism of Resistance to Cisplatin” Inorganic
Chemistry. Englewood Cliffs, NJ: Prentice–Hall; 2001.
5) Anti-cancer Agents: A treatment of Cisplatin and their analogues “http://www2.mrclmb.cam.ac.uk/personal/sl/Html/Frames.html” assessed on Nov 2007
6) Reedijk, J. Chem. Commun., 1996 801–806
7) Jan Reedijk* “ New clues for platinum antitumor chemistry: Kinetically controlled metal
binding to DNA” Bioinorganic Chemistry Special Feature 2003, 100 ( 7 ) 3611–3616
8) Miloviae, N.M;Dutca, L.M. “ Transition – metal complexes as enzyme – like reagents for
protein cleavage: Complex cis–[Pt(en)(H2O)2]2+ as a methionine protease”. Chemical.
European. Journal.2003 9, (20), 5097 – 5106
9) Jansen, B. A .J; Brouwer, J.; Redijk, J. “Glutathione induce cellular resistance against
cationic dinuclear platinum anticancer drugs”. J. Inorg. Biochem. 2002, 89, (3-4), 197 202
10) Peleg-Shulman, T.: Najajreh, Y.; Gibson,D. “ Interaction of cisplatin and transplatin with
protein. Comparison of binding kinetics, binding sites and reactivity of Pt – protein
adducts of cisplatin and transplatin towards biological nucleophiles”. J. Inorg. Biochem.
2002, 91, (1), 306 -311
11) Choi S, Delaney S, Orbai L, Padgett E J, Hakemian A S.” A platinum (IV) complex
oxidizes guanine to 8-oxo-guanine in DNA and RNA.” Inorg Chem. 2001, 4, 5481–5486.
12) Lippert B.” Impact of cisplatin on the recent development of Pt coordination chemistry: a
case study” Coord. Chem. Rev. 1999; 182;263–295.

38

39
13) Michele Benedetti, Jaroslav Malina, Jana Kasparkova, Viktor Brabec, Giovanni Natile
“Chiral Discrimination in Platinum Anticancer Drugs” Environmental Health
Perspectives, 2002 110, 5 pp. 779-782: Molecular Mechanisms of Metal Toxicity and
Carcinogenicity
14) Liu X, Kim C, Yang J, Jemmerson R, Wang X. "Induction of apoptotic program in cellfree extracts: requirement for dATP and cytochrome c".1996 American Association for
Cancer Research, 86 (1): 147–57.
15) HENKELS K.M;TURCHI J. J.;“Cisplatin-induced apoptosis proceeds by caspase-3dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian
cancer cell lines” American Association for Cancer Research INIST-CNRS, Cote INIST :
5088, 35400008582547.0130 assessed on Mar 2008
16) Zejia Yang, Lisa M. Schumaker “Cisplatin Preferentially Binds Mitochondrial DNA and
Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and
Neck Squamous Cell Carcinoma: Possible Role in Apoptosis” Clinical Cancer Research
October 1, 2006, Vol. 12, 5817-5825
17) Reedijk, J “Platinum-Sulfur Interactions Involved in Antitumor Drugs, Rescue Agents,
and Biomolecules” Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug.
Lippert B., editor. Weinheim, Germany: Wiley; 1999. pp. 339–362
18) Williams, K.M.; Rowan, C.; Mitchell, J. “Effect of Amine Ligand Bulk on the Interaction
of Methionine with Platinum(II) Diamine Complexes”, Inorg. Chem., 2004, 43, 11901196.

